Literature DB >> 32128517

An Evaluation of the Effects of Betahistine and Dimenhydrinate on Posterior Canal Benign Paroxysmal Positional Vertigo.

Hakkı Caner İnan1, Merve Kıraç1.   

Abstract

OBJECTIVE: Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular system disease causing dizziness. It occurs more in the 5th decade of life and affects the posterior canal in 90% of the patients. The most effective treatment method is canalith repositioning (CRP) maneuver. The aim of this study is to evaluate the effects of betahistine and dimenhydrinate therapies in addition to CRP maneuver on BPPV patients.
METHODS: The study included 64 patients who had complaints of dizziness and were diagnosed with BPPV by their history and provocation maneuvers. The patients were divided into two groups. In Group 1, only repositioning maneuver was performed. Group 2 was divided into two subgroups. In Group 2a, repositioning maneuver was performed and betahistine 24 mg twice daily was given for 10 days. In Group 2b, repositioning maneuver was performed and dimenhydrinate 50 mg once daily was given for five days. On the 10th day, all patients were reexamined, and provocation maneuver was performed. Dizziness handicap inventory (DHI) was completed and outcomes were reviewed for therapeutic efficacy.
RESULTS: Mean DHI scores in all patient groups statistically significantly decreased from a pre-treatment level of 52.16 (range, 20-100) to a post-treatment level of 17.84 (range, 0-78) (p<0.001). No statistically significant differences were found in terms of DHI scores between Group 1 (repositioning maneuver only) and Group 2 (repositioning maneuver plus betahistine or dimenhydrinate).
CONCLUSION: The most effective treatment method of BPPV is repositioning maneuver. Addition of betahistine or dimenhydrinate pharmacotherapy to repositioning maneuver did not show superiority to treatment with repositioning maneuvers alone. © Copyright 2019 by Official Journal of the Turkish Society of Otorhinolaryngology and Head and Neck Surgery.

Entities:  

Keywords:  Benign paroxysmal positional vertigo; Epley maneuver; canalith repositioning maneuver; pharmacotherapy

Year:  2019        PMID: 32128517      PMCID: PMC7032557          DOI: 10.5152/tao.2019.4185

Source DB:  PubMed          Journal:  Turk Arch Otorhinolaryngol        ISSN: 2667-7466


  21 in total

Review 1.  Development and maintenance of otoconia: biochemical considerations.

Authors:  R Thalmann; E Ignatova; B Kachar; D M Ornitz; I Thalmann
Journal:  Ann N Y Acad Sci       Date:  2001-10       Impact factor: 5.691

2.  The development of the Dizziness Handicap Inventory.

Authors:  G P Jacobson; C W Newman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-04

Review 3.  Clinical practice. Benign paroxysmal positional vertigo.

Authors:  Ji-Soo Kim; David S Zee
Journal:  N Engl J Med       Date:  2014-03-20       Impact factor: 91.245

4.  Benign paroxysmal positional vertigo (BPPV): influence of pharmacotherapy and rehabilitation therapy on patients' recovery rate and life quality.

Authors:  Sinisa Maslovara; Silva Butkovic Soldo; Mirjana Puksec; Branka Balaban; Ivana Pajic Penavic
Journal:  NeuroRehabilitation       Date:  2012       Impact factor: 2.138

5.  Benign paroxysmal positional vertigo--a review of 101 cases.

Authors:  Clara Silva; Ana Margarida Amorim; António Paiva
Journal:  Acta Otorrinolaringol Esp       Date:  2015-04-09

Review 6.  Classification, diagnostic criteria and management of benign paroxysmal positional vertigo.

Authors:  Takao Imai; Noriaki Takeda; Tetsuo Ikezono; Kohichiro Shigeno; Masatsugu Asai; Yukio Watanabe; Mamoru Suzuki
Journal:  Auris Nasus Larynx       Date:  2016-05-09       Impact factor: 1.863

7.  Traumatic versus Idiopathic Benign Positional Vertigo: Analysis of Disease, Treatment, and Outcome Characteristics.

Authors:  Alexander L Luryi; Michael LaRouere; Seilesh Babu; Dennis I Bojrab; John Zappia; Eric W Sargent; Christopher A Schutt
Journal:  Otolaryngol Head Neck Surg       Date:  2018-10-16       Impact factor: 3.497

8.  Probable Benign Paroxysmal Positional Vertigo Converts into Definite BPPV in One in Six Patients.

Authors:  Hester van der Zaag-Loonen; Tjasse Bruintjes; Roeland van Leeuwen
Journal:  J Int Adv Otol       Date:  2018-12       Impact factor: 1.017

9.  Efficacy of betahistine plus cognitive behavioral therapy on residual dizziness after successful canalith repositioning procedure for benign paroxysmal positional vertigo.

Authors:  Tian-Ju Wan; Yi-Chuan Yu; Xiao-Gang Zhao; Ping Tang; Yong-Shu Gong
Journal:  Neuropsychiatr Dis Treat       Date:  2018-11-05       Impact factor: 2.570

10.  Clinical features of benign paroxysmal positional vertigo of the posterior semicircular canal.

Authors:  Andrea Ciorba; Cristina Cogliandolo; Chiara Bianchini; Claudia Aimoni; Stefano Pelucchi; Piotr Henryk Skarżyński; Stavros Hatzopoulos
Journal:  SAGE Open Med       Date:  2019-01-02
View more
  1 in total

1.  Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway.

Authors:  Jing Hui; Qi Lei; Zhi Ji; Dingjing Zi
Journal:  Biol Res       Date:  2022-04-04       Impact factor: 5.612

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.